Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 8158126
Stem cell fusion model of carcinogenesis
granted -
US 8158754
Multiple modified derivatives of gelatin and crosslinked material thereof
granted -
US 8158364
Methods and compositions involving nucleotide repeat disorders
granted -
US 8153604
CNS-tumor treatment method and composition
granted -
US 8153620
Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
granted -
US 8153103
Conjugates of photo-activatable dyes
granted -
US 8153136
Yeast-based vaccines as immunotherapy
granted -
US 8147828
Methods and compositions for modulation of blood-neural barrier
granted -
US 8148149
Methods of inducing tubulogenesis and/or branching morphogenesis of kidney cell cultures
granted -
US 8148328
Salicylanilides enhance oral delivery of therapeutic peptides
granted -
US 8148510
Antifungal polypeptides
granted -
US 8148352
Antimicrobial therapy for bacterial infections
granted -
US 8147805
Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications
granted -
US 8147833
Prevention and treatment of synucleinopathic and amyloidogenic disease
granted -
US 8143295
Compounds having activity in correcting mutant-CFTR processing and uses thereof
granted -
US 8143226
Tyrosine kinase receptor antagonists and methods of treatment for breast cancer
granted -
US 8143412
Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs)
granted -
US 8142809
Compositions and methods to lower glycohemoglobin levels
granted -
US 8143232
Gene fusion targeted therapy
granted -
US 8143418
Dimeric small molecule potentiators of apoptosis
granted -
US 8143218
Treatment of skin, and wound repair, with thymosin beta 4
granted -
US 8137672
Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
granted -
US 8138312
Compositions for regulation of tumor necrosis factor-alpha
granted -
US 8138310
Chimeric CD154 polypeptides
granted -
US 8133902
Ammosamides as anticancer agents
granted -
US 8133496
Compositions and methods for diagnosing and treating urinary tract infections
granted -
US 8133915
Interleukin-1 and tumor necrosis factor-Ξ± modulators; syntheses of such modulators and methods of using such modulators
granted -
US 8129433
Enterically coated cysteamine, cystamine and derivatives thereof
granted -
US 8129332
Reagents and methods for smooth muscle therapies
granted -
US 8129334
Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
granted -
US 8128924
Methods for using a three-dimensional stromal tissue to promote angiogenesis
granted -
US 8128939
Mutants of cholesterol-dependent cytolysins and uses thereof
granted -
US 8129341
Methods for treating diabetic wounds
granted -
US 8129335
Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry
granted -
US 8129349
Treatment of disease by inducing cell apoptosis
granted -
US 8124653
Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
granted -
US 8124068
Recombinant intracellular pathogen immunogenic compositions and methods of use
granted -
US 8124109
Vault compositions for immunization against chlamydia genital infection
granted -
US 8124110
Proteins with repetitive bacterial-Ig-like (Big) domains present in Leptospira species
granted -
US 8124579
Heat shock protein 20-related polypeptides and uses therefor
granted -
US 8124651
Palmarumycin based inhibitors of thioredoxin and methods of using same
granted -
US 8119660
Small-molecule inhibitors of the androgen receptor
granted -
US 8119827
Compounds for treatment of cell proliferative diseases
granted -
US 8119649
Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
granted -
US 8119618
Compositions and methods for the treatment of inflammatory diseases
granted -
US 8119772
MART-1 T cell receptors
granted -
US 8119656
Inhibitors of the influenza virus non-structural 1 protein
granted -
US 8114618
Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory